Kofituss Sedativo Tosse (Levodropropizine)

Levodropropizine works peripherally by desensitizing cough receptors located in the airway epithelium. This reduces the receptors’ response to mechanical and chemical stimuli, thereby lowering the afferent signal that triggers the cough reflex. Because it does not cross the blood‑brain barrier, it avoids central nervous system effects typical of opioid‑based cough suppressants.

The appropriate dose of Kofituss Sedativo Tosse is determined by the prescribing healthcare professional based on the patient’s age, weight, and severity of symptoms. The prescriber will select the formulation strength and dosing frequency that best matches the individual’s therapeutic needs, following local labeling recommendations.

Safety data for levodropropizine in pregnancy and lactation are limited. It should be used only if the potential benefit outweighs any possible risk to the fetus or infant. Healthcare providers typically advise caution and may recommend alternative therapies when safer options are available.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Unlike centrally acting opioid antitussives such as codeine, levodropropizine acts peripherally and does not cause significant sedation or respiratory depression. This makes it a preferable option for patients who need cough relief without the central nervous system side effects associated with opioid‑based products.

Kofituss Sedativo Tosse should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

The medication is taken orally, usually as a tablet or liquid preparation, according to the prescriber’s instructions. It can be swallowed with or without food; if a liquid form is used, it should be measured with a calibrated device to ensure accurate dosing.

Serious adverse reactions, although rare, include allergic responses such as rash, urticaria, angioedema, and in extreme cases anaphylaxis. Hepatic dysfunction and severe neutropenia have also been reported. Patients should seek immediate medical attention if they experience swelling of the face or lips, difficulty breathing, or signs of liver injury.

Individuals with a known hypersensitivity to levodropropizine or any excipients in the formulation should avoid the product. Patients with severe hepatic impairment, uncontrolled asthma, or those taking contraindicated medications (e.g., monoamine oxidase inhibitors) should also refrain from use unless directed by a healthcare professional.